TG Therapeutics TGTX Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's non-cash lease expense?
- TG Therapeutics (TGTX) reported non-cash lease expense of $573K in Q1 2026.
- How has TG Therapeutics's non-cash lease expense changed year-over-year?
- TG Therapeutics's non-cash lease expense increased by 26.5% year-over-year, from $453K to $573K.
- What is the long-term trend for TG Therapeutics's non-cash lease expense?
- Over 4 years (2021 to 2025), TG Therapeutics's non-cash lease expense has grown at a -2.0% compound annual growth rate (CAGR), from $1.9M to $1.75M.
- What does non-cash lease expense mean?
- The non-cash accounting charge for the use of leased assets like offices or equipment.
- How do you interpret non-cash lease expense?
- Stable levels indicate consistent lease obligations, while changes reflect shifts in facility footprint.
- How does non-cash lease expense compare across companies?
- Standard for all companies reporting under modern lease accounting standards.